Cargando…

Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials

AIMS: Several randomized trials and a previous meta-analysis have shown significant benefits from Gp IIb-IIIa inhibitors, especially abciximab. Recent randomized trials (BRAVE-3 and HORIZON trials) have shown no benefits from adjunctive Gp IIb-IIIa inhibitors on the top of clopidogrel administration...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Luca, Giuseppe, Navarese, Eliano, Marino, Paolo
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2009
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777025/ https://www.ncbi.nlm.nih.gov/pubmed/19875386 http://dx.doi.org/10.1093/eurheartj/ehp118

Ejemplares similares

Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor
por: Cho, Jung Sun, et al.
Publicado: (2010)

Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction
por: Howard, J. P., et al.
Publicado: (2014)

Value of C-Reactive Protein in Predicting Left Ventricular Remodelling in Patients with a First ST-Segment Elevation Myocardial Infarction
por: Swiatkiewicz, Iwona, et al.
Publicado: (2012)

Impact of coronary angioplasty in elderly patients with non-ST-segment elevation myocardial infarction
por: Gonçalves, Fernando F., et al.
Publicado: (2020)

Receptor GP IIb/IIIa as an Indicator of Risk in Vascular Events
por: Fiodorenko-Dumas, Żanna, et al.
Publicado: (2019)

Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial
por: Zeymer, Uwe, et al.
Publicado: (2014)

The impact of ischemia-reperfusion injury on the effectiveness of primary angioplasty in ST-segment elevation myocardial infarction
por: Araszkiewicz, Aleksander, et al.
Publicado: (2013)

Acute Cerebral Infarction Following Intravenous Glycoprotein IIb/IIIa Inhibitor for Acute Myocardial Infarction
por: Choi, Woong Gil, et al.
Publicado: (2011)

Risk Factors of Reperfusion Failure following Primary Angioplasty for ST-Segment Elevation Myocardial Infarction (STEMI)
por: Sanati, Hamid Reza, et al.
Publicado: (2013)

Intracoronary Glycoprotein IIb/IIIa Inhibitors Improve Short-Term Mortality and Reinfarction in East Asian Patients with ST-Segment Elevation Myocardial Infarction after Thrombus Aspiration: A Meta-Analysis
por: Wu, Jia-hong, et al.
Publicado: (2018)

Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases
por: Abdeladim, Salma, et al.
Publicado: (2021)

Glycoprotein IIb/IIIa inhibitors for cardiogenic shock complicating acute myocardial infarction: a systematic review, meta-analysis, and meta-regression
por: Saleiro, Carolina, et al.
Publicado: (2020)

Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study
por: Adamski, Piotr, et al.
Publicado: (2017)

Patient delay and benefit of timely reperfusion in ST-segment elevation myocardial infarction
por: Scholz, Karl Heinrich, et al.
Publicado: (2021)

Characteristics and mechanism of reciprocal ST-segment depression in acute ST segment elevation myocardial infarction: Reciprocal ST-segment depression and ST segment elevation myocardial infarction
por: Gao, Qijun, et al.
Publicado: (2022)

Early glycoprotein IIb–IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis
por: De Luca, G, et al.
Publicado: (2008)

First Human Use of RUC‐4: A Nonactivating Second‐Generation Small‐Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point‐of‐Care Treatment of ST‐Segment–Elevation Myocardial Infarction
por: Kereiakes, Dean J., et al.
Publicado: (2020)

Symptom onset to balloon time in patients with ST-segment elevation myocardial infarction treated by primary coronary angioplasty: influence on ST-segment resolution and on mortality
por: Assi, E Abu, et al.
Publicado: (2007)

An embolic ST-segment elevation myocardial infarction
por: Feng, Lv, et al.
Publicado: (2021)

Acute ST-segment elevation myocardial infarction: to be or not to be?
por: Barbur, Maria Carolina Manzur, et al.
Publicado: (2022)

Platelet Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndromes and Percutaneous Coronary Intervention: Glycoprotein IIb/IIIa Inhibitors, Clopidogrel, or Both?
por: Silva, Matthew A, et al.
Publicado: (2006)

Left ventricular function, strain, and infarct characteristics in patients with transient ST-segment elevation myocardial infarction compared to ST-segment and non-ST-segment elevation myocardial infarctions
por: Demirkiran, Ahmet, et al.
Publicado: (2021)

Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction
por: Fernández-Bergés, Daniel, et al.
Publicado: (2020)

Primary coronary angioplasty for ST-Elevation Myocardial Infarction in Qatar: First nationwide program
por: Gehani, Abdurrazzak, et al.
Publicado: (2013)

Management of ST elevation myocardial infarction (STEMI) with primary angioplasty in Covid 19 lockdown
por: Kumar, Manoj, et al.
Publicado: (2020)

GP IIb/IIIa Receptor Inhibitors in Mechanically Ventilated Patients with Cardiogenic Shock due to Myocardial Infarction in the Era of Potent P2Y12 Receptor Antagonists
por: Kanic, Vojko, et al.
Publicado: (2022)

Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre‐treated with newer P2Y12 inhibitors
por: Blanchart, Katrien, et al.
Publicado: (2021)

False Positive ST-Segment Elevation Myocardial Infarction
por: Jeong, Hae Chang, et al.
Publicado: (2013)

Etiologies and Predictors of ST-Segment Elevation Myocardial Infarction
por: Bae, Myung Hwan, et al.
Publicado: (2013)

Anemia and Inflammation in ST-Segment Elevation Myocardial Infarction
por: Zhang, Enyuan, et al.
Publicado: (2015)

Actual Role of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors as Adjunctive Pharmacological Therapy to Primary Angioplasty in Acute Myocardial Infarction: In the Light of Recent Randomized Trials and Observational Studies with Bivalirudin
por: Centurión, Osmar Antonio
Publicado: (2010)

Impact of ST‐Segment–Elevation Myocardial Infarction Regionalization Programs on the Treatment and Outcomes of Patients Diagnosed With Non–ST‐Segment–Elevation Myocardial Infarction
por: Montoy, Juan Carlos C., et al.
Publicado: (2021)

LASSO Regression-Based Diagnosis of Acute ST-Segment Elevation Myocardial Infarction (STEMI) on Electrocardiogram (ECG)
por: Wu, Lin, et al.
Publicado: (2022)

One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock
por: Myrda, Krzysztof, et al.
Publicado: (2021)

ST-segment resolution as a marker for severe myocardial fibrosis in ST-segment elevation myocardial infarction
por: Dong, Qian, et al.
Publicado: (2021)

Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke
por: Lee, John-Ih, et al.
Publicado: (2017)

aVR ST‐segment changes and prognosis of ST‐segment elevation myocardial infarction
por: Sedighi, Sogol, et al.
Publicado: (2021)

Role of Gender on the Outcomes of ST-Elevation Myocardial Infarction Patients Following Primary Coronary Angioplasty
por: Heydari, Aigin, et al.
Publicado: (2021)

Diagnostic Accuracy of Adenosine Stress Cardiovascular Magnetic Resonance Following Acute ST-segment Elevation Myocardial Infarction Post Primary Angioplasty
por: Wong, Dennis TL, et al.
Publicado: (2011)

Citicoline Modifies the Expression of Specific miRNAs Related to Cardioprotection in Patients with ST-Segment Elevation Myocardial Infarction Subjected to Coronary Angioplasty
por: Silva-Palacios, Alejandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_64v0b6qg2mfe8q8i67emru2cdf